Functional polymorphisms, altered gene expression and genetic association link NRH:quinone oxidoreductase 2 to breast cancer with wild-type p53

Human Molecular Genetics

Volumn 18, Issue 13, 2009, Pages 2502-2517

  Yu, Ke Da ^a   Di, Gen Hong ^a   Yuan, Wen Tao ^b   Fan, Lei ^a   Wu, Jiong ^a   Hu, Zhen ^a   Shen, Zhen Zhou ^a   Zheng, Ying ^c   Huang, Wei ^b   Shao, Zhi Ming ^a  

^a FUDAN UNIVERSITY   (China)

^b CHINESE NATIONAL HUMAN GENOME CENTER AT SHANGHAI   (China)

^c SHANGHAI MUNICIPAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; OXIDOREDUCTASE; PROTEIN P53; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE QUINONE OXIDOREDUCTASE 2; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

ADULT; ALLELE; ANIMAL CELL; ARTICLE; BINDING SITE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER INCIDENCE; CANCER RISK; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE EXPRESSION; GENE INSERTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BASE SEQUENCE; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CHINA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; QUINONE REDUCTASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 67249150968     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddp171     Document Type: Article

References (51)

1. Yager, J.D. and Davidson, N.E. (2006) Estrogen carcinogenesis in breast cancer. N. Engl. J. Med., 354, 270-282.
2. Le Marchand, L., Donlon, T., Kolonel, L.N., Henderson, B.E. and Wilkens, L.R. (2005) Estrogen metabolism-related genes and breast cancer risk: the multiethnic cohort study. Cancer Epidemiol. Biomarkers Prev., 14, 1998-2003.
3. Haiman, C.A., Stram, D.O., Pike, M.C., Kolonel, L.N., Burtt, N.P., Altshuler, D., Hirschhorn, J. and Henderson, B.E. (2003) A comprehensive haplotype analysis of CYP19 and breast cancer risk: The Multiethnic Cohort. Hum. Mol. Genet., 12, 2679-2692.
4. Li, K.M., Todorovic, R., Devanesan, P., Higginbotham, S., Kofeler, H., Ramanathan, R., Gross, M.L., Rogan, E.G. and Cavalieri, E.L. (2004) Metabolism and DNA binding studies of 4-hydroxyestradiol and estradiol-3,4-quinone in vitro and in female ACI rat mammary gland in vivo. Carcinogenesis, 25, 289-297.
5. Talalay, P. (1989) Mechanisms of induction of enzymes that protect against chemical carcinogenesis. Adv. Enzyme Regul., 28, 237-250.
6. Jaiswal, A.K. (2000) Characterization and partial purification of microsomal NAD(P)H:qUinone oxidoreductases. Arch. Biochem. Biophys. 375, 62-68.
7. Menzel, H.J., Sarmanova, J., Soucek, P., Berberich, R., Grunewald, K., Haun, M. and Kraft, H.G. (2004) Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations. Br. J. Cancer, 90, 1989-1994.
8. Fagerholm, R., Hofstetter, B., Tommiska, J., Aaltonen, K., Vrtel, R., Syrjakoski, K., Kallioniemi, A., Kilpivaara, O., Mannermaa, A., Kosma, V.M. et al. (2008) NAD(P)H:qUinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat. Genet., 40, 844-853.
9. Long, D.J. and Jaiswal, A.K. (2000) NRH:qUinone oxidoreductase2 (NQO2). Chem. Biol. Interact., 129, 99-112.
10. Celli, C.M., Tran, N., Knox, R. and Jaiswal, A.K. (2006) NRH:qUinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs. Biochem. Pharmacol., 72, 366-376.
11. Harada, S., Fujii, C., Hayashi, A. and Ohkoshi, N. (2001) An association between idiopathic Parkinson's disease and polymorphisms of phase II detoxification enzymes: Glutathione S-transferase M1 and quinone oxidoreductase 1 and 2. Biochem. Biophys. Res. Commun., 288, 887-892.
12. Iskander, K., Paquet, M., Brayton, C. and Jaiswal, A.K. (2004) Deficiency of NRH:qUinone oxidoreductase 2 increases susceptibility to 7,12-dimethylbenzva)anthracene and benzo(a)pyrene-induced skin carcinogenesis. Cancer Res., 64, 5925-5928.
13. Gaikwad, N.W., Yang, L., Rogan, E.G. and Cavalieri, E.L. (2009) Evidence for NQO2-mediated reduction of the carcinogenic estrogen ortho-quinones. Free Radic. Biol. Med., 46, 253-262.
14. Gong, X., Kole, L., Iskander, K. and Jaiswal, A.K. (2007) NRH:qUinone oxidoreductase 2 and NAD(P)H:qUinone oxidoreductase 1 protect tumor suppressor p53 against 20s proteasomal degradation leading to stabilization and activation of p53. Cancer Res., 67, 5380-5388.
15. Liu, X., Holstege, H., van der Gulden, H., Treur-Mulder, M., Zevenhoven, J., Velds, A., Kerkhoven, R.M., van Vliet, M.H., Wessels, L.F., Peterse, J.L. et al. (2007) Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc. Natl Acad. Sci. USA, 104, 12111-12116.
16. Orphanos, V., McGown, G., Hey, Y., Boyle, J.M. and Santibanez-Koref, M. (1995) Proximal 6q, a region showing allele loss in primary breast cancer. Br. J. Cancer, 71, 290-293.
17. Piao, Z., Lee, K.S., Kim, H., Perucho, M. and Malkhosyan, S. (2001) Identification of novel deletion regions on chromosome arms 2q and 6p in breast carcinomas by amplotype analysis. Genes Chromosomes Cancer, 30, 113-122.
18. Lerebours, F., Bertheau, P., Bieche, I., Driouch, K., De The, H., Hacene, K., Espie, M., Marty, M. and Lidereau, R. (2002) Evidence of chromosome regions and gene involvement in inflammatory breast cancer. Int. J. Cancer, 102, 618-622.
19. Wang, W., Le, W.D., Pan, T., Stringer, J.L. and Jaiswal, A.K. (2008) Association of NRH:qUinone oxidoreductase 2 gene promoter polymorphism with higher gene expression and increased susceptibility to Parkinson's disease. J. Gerontol. A Biol. Sci. Med. Sci., 63, 127-134.
20. Gyorffy, B., Kocsis, I. and Vasarhelyi, B. (2004) Missed calculations and new conclusions: Re-calculation of genotype distribution data published in Journal of Investigative Dermatology, 1998-2003. J. Invest. Dermatol., 122, 644-646.
21. Deng, H.W., Chen, W.M. and Recker, R.R. (2001) Population admixture: detection by Hardy-Weinberg test and its quantitative effects on linkage-disequilibrium methods for localizing genes underlying complex traits. Genetics, 157, 885-897.
22. Wittke-Thompson, J.K., Pluzhnikov, A. and Cox, N.J. (2005) Rational inferences about departures from Hardy-Weinberg equilibrium. Am. J. Hum. Genet., 76, 967-986.
23. Gabriel, S.B., Schaffner, S.F., Nguyen, H., Moore, J.M., Roy, J., Blumenstiel, B., Higgins, J., DeFelice, M., Lochner, A., Faggart, M. et al. (2002) The structure of haplotype blocks in the human genome. Science, 296, 2225-2229.
24. Yin, W.J., Lu, J.S., Di, G.H., Lin, Y.P., Zhou, L.H., Liu, G.Y., Wu, J., Shen, K.W., Han, Q.X., Shen, Z.Z. et al. (2008) Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. Breast Cancer Res. Treat. In press.
25. Scheet, P. and Stephens, M. (2006) A fast and flexible statistical model for large-scale population genotype data: Applications to inferring missing genotypes and haplotypic phase. Am. J Hum. Genet., 78 629-644.
26. Wang, W. and Jaiswal, A.K. (2O04) Sp3 repression of polymorphic human NRH:qUinone oxidoreductase 2 gene promoter. Free Radic. Biol. Med. 37, 1231-1243.
27. Strassburg, A., Strassburg, C.P., Manns, M.P. and Tukey, R.H. (2002) Differential gene expression of NAD(P)H:qUinone oxidoreductase and NRH:qUinone oxidoreductase in human hepatocellular and biliary tissue. Mol Pharmacol., 61, 320-325.
28. Walsk T. and King, M.C. (2007) Ten genes for inherited breast cancer. Cancer Cell, 11, 103-105.
29. Johnson, N., Fletcher, O., Palles, C., Rudd, M., Webb, E., Sellick, G., dos Santos Silva, L, McCormack, V., Gibson, L., Fraser, A. et al. (2007) Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. Hum. Mol. Genet., 16, 1051-1057.
30. Chen, P., Liang, J., Wang, Z., Zhou, X., Chen, L., Li, M., Xie, D., Hu, Z., Shen, H. and Wang, H. (2008) Association of common PALB2 polymorphisms with breast cancer risk: A case-control study. Clin. Cancer Res., 14, 5931-5937.
31. Song, H., Ramus; S.J., Kjaer, S.K., Hogdall, E;, Dicioccio, R.A., Whittemore, A.S., McGuire, V., Hogdall, C., Jacobs, I.J., Easton, D.F. et al. (2007) Tagging single nucleotide polymorphisms in the BRIP1 gene and susceptibility to breast and ovarian cancer. PLoS ONE, 2, e268.
32. Peto, J. (2002) Breast cancer susceptibility-A new look at an old model. Cancer Cell, 1, 411-412.
33. Easton, D.F., Pooley, K.A., Dunning, A.M., Pharoah, P.D., Thompson, D., Ballinger, D.G., Stmewing, J.P., Morrison, J., Field, H., Luben, R. et al. (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature, 447, 1087-1093.
34. Easton, D.F. and Eeles, R.A. (2008) Genome-wide association studies in cancer. Hum. Mol. Genet., 17, R109-R115.
35. Li, W.F., Hu, Z., Rao, N.Y., Song, C.G., Zhang, B., Cao, M.Z., Su, FX, Wang, Y.S., He, P.Q., Di, G.H. et al. (2008) The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: Two recurrent mutations were identified. Breast Cancer Res. Treat., 110, 99-109.
36. Cao, A.Y., Huang, J., Hu, Z., Li, W.F., Ma, Z.L., Tang, L.L., Zhang, B., Su, F.X., Zhou, J., Di, G.H. et al. (2008) Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives. Breast Cancer Res. Treat. In press.
37. Cao, A.Y., Huang, J., Hu, Z., Li, W.F., Ma, Z.L., Tang, L.L., Zhang, B., Su, FX, Zhou, J., Di, G.H. et al. (2009) The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives. Breast Cancer Res. Treat. 114, 457-462.
38. Sensi, E., Tancredi, M., Aretini, P., Cipollini, G., Naccarato, A.G., Viacava, P., Bevilacqua, G. and Caligo, M.A. (2003) p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations. Breast Cancer Res. Treat., 82, 1-9.
39. Frebourg, T., Barbier, N., Yan, YX, Garber, J.E., Dreyfus, M., Fraumeni, J. Jr, Li, F.P. and Friend, S.H. (1995) Germ-line p53 mutations in 15 families with Li-Fraurneni syndrome. Am. J. Hum. Genet., 56, 608-615.
40. Walsh, T., Casadei, S., Coats, K.H., Swisher, E., Stray, S.M., Higgins, J., Roach, K.C., Mandell, I., Lee, M.K., Ciernikova, S. et al. (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2 and TP53 in families at high risk of breast cancer. JAMA, 295, 1379-1388.
41. Coles, C., Condie, A., Chetty, U., Steel, C.M., Evans, H.J. and Prosser, J. (1992) p53 mutations in breast cancer. Cancer Res., 52, 5291-5298.
42. Hartman, A., Blaszyk, H., Saitoh, S., Tsushima, K., Tamura, Y., Cunningham, J.M., McGovern, R.M., Schroeder, J.J., Sommer, S.S. and Kovach, LS. (1996) High frequency of p53 gene mutations in primary breast cancers in Japanese women, a low-incidence population. Br. J. Cancer, 73, 896-901.
43. Visakorpi, T., Kallioniemi, O.P., Heikkinen, A., Koivula, T. and Isola, J, (1992) Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J. Natl. Cancer Inst., 84, 883-887.
44. Alsner, J., Jensen, V., Kyndi, M., Offersen, B.V., Vu, P., Borresen-Dale, A.L. and Overgaard, J. (2008) A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancqr patients. Acta Oncol., 47, 600-607.
45. Ghayor, C., Chadjichristos, C., Herrouin, J.F., Ala-Kokko, L., Suske, G., Pujol, J.P. and Galera, P. (2001) Sp3 represses the Sp1-mediated transactivation of the human COL2A1 gene in primary and de-differeneated chondrocytes. J. Biol. Chem., 276, 36881-36895.
46. Santen, R.J. and Mansel, R. (2005) Benign breast disorders. N. Engl. J. Med., 353, 275-285.
47. Yu, K.D., Di, G.H., Wu, J., Lu, J.S., Shen, K.W., Shen, ZZ and Shao, Z.M. (2007) Development and trends of surgical modalities for breast cancer in china: A review of 16-year data. Ann. Surg. Oncol., 14, 2502-2509.
48. Song, C.G., Hu, Z., Wu, J., Luo, J.M., Shen, ZZ, Huang, W. and Shao, Z.M. (2006) The prevalence of BRCA1 and BRCA2 mutations in eastern Chinese women with breast cancer. J Cancer Res. Clin. Oncol., 132, 617-626.
49. Bell, P.A., Chaturvedi, S., Gelfand, C.A., Huang, C.Y., Kochersperger, M., Kopla, R., Modica, F., Pohl, M., Varde, S, Zhao, It, et al. (2002) SNPstream UHT: Ultra-high throughput SNP genotyping for pharmacogenomics and drug discovery. Biotechniques, 32 Suppl.), 70-72, 74, 76-77.
50. Moshynska, O., Moshynskyy, I., Misra, V. and Saxena, A. (2005) G125A single-nucleotide polymorphism in theliuman BAX promoter affects expression. Oncogene, 24, 2042-2049.
51. Aldea, C., Alvarez, C.P., Folgueira, L., Delgado, R. and Otero, J.R. (2002) Rapid detection of herpes simplex. virus DNA in genital ulcers by real-time PCR using SYBR green I dye as the detection signal. J. Clin. Microbiol., 40, 1060-1062.